KPI data tables
Moderna operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash + investments ($B) |
|---|---|
| Q3 2026 | 7.976 |
| Q2 2026 | 6.91 |
| Q1 2026 | 7.456 |
| Q4 2025 | 8.135 |
| Q3 2025 | 6.647 |
| Q2 2025 | 7.505 |
| Q1 2025 | 8.393 |
| Q4 2024 | 9.519 |
| Q3 2024 | 9.202 |
| Q2 2024 | 10.814 |
| Q1 2024 | 12.161 |
| Q4 2023 | 13.281 |
| Q3 2023 | 12.846 |
| Q2 2023 | 14.564 |
| Q1 2023 | 16.365 |
| Q4 2022 | 18.22 |
| Q3 2022 | 17.003 |
| Q2 2022 | 18.059 |
| Q1 2022 | 19.286 |
| Q4 2021 | 17.57 |
| Q3 2021 | 15.348 |
Source: Moderna Exhibit 99.1 condensed consolidated balance sheets, cash plus investments plus investments, non-current (millions, divided by 1,000). SEC XBRL https://data.sec.gov/api/xbrl/companyfacts/CIK0001682852.json tags CashAndCashEquivalentsAtCarryingValue + AvailableForSaleSecuritiesDebtSecuritiesCurrent + AvailableForSaleSecuritiesDebtSecuritiesNoncurrent sum to the same liquidity total on overlapping quarter-ends; later 10-Q/10-K filing wins. Series Q3 2021–Q3 2026. Q4 2024: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/exhibit9912024q4pressrelea.htm ($1,927 + $5,098 + $2,494 million). Q1 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm ($1,623 + $4,352 + $2,418 million). Q2 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/exhibit9912025q2pressrelea.htm ($1,279 + $3,852 + $2,374 million). Q3 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/exhibit9912025q3pressrelea.htm ($1,132 + $3,372 + $2,143 million). Q4 2025: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/exhibit9912025q4pressrelea.htm ($2,595 + $3,204 + $2,336 million). Q1 2026: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/exhibit9912026q1pressrelea.htm ($1,908 + $3,297 + $2,251 million). Q2 2026: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm ($1,723 + $3,415 + $1,772 million). Q3 2026: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000194/exhibit9912026q3pressrelea.htm ($1,195 + $3,976 + $2,805 million), filed 2026-11-06. Convertible notes: Form 8-K filed 1 Sep 2026, https://www.sec.gov/Archives/edgar/data/1682852/000119312526378505/d108896d8k.htm. Year-end 2026 outlook $8.1 to $8.3 billion is the Q3 2026 Exhibit 99.1 cash-and-investments framework and is not charted.
| Period | COVID (Spikevax and mNEXSPIKE) | RSV (mRESVIA) |
|---|---|---|
| FY2025 | 1.81 | 0.008 |
| FY2024 | 3.084 | 0.025 |
| FY2023 | 6.671 | 0 |
Source: Moderna FY2025 Form 10-K Note, net product sales by product (https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/R24.htm and https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm). COVID includes Spikevax and mNEXSPIKE. FY2023 COVID $6,671 million, RSV not commercial. FY2024 COVID $3,084 million, RSV $25 million. FY2025 COVID $1,810 million, RSV $8 million. Totals $6,671 / $3,109 / $1,818 million match the net product sales line. Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/R11.htm) repeats that mCOMBRIAX was not commercialized as of 30 Jun 2026.
| Period | Stand-ready manufacturing | Grant | Collaboration | Licensing and royalty |
|---|---|---|---|---|
| FY2025 | 80 | 22 | 13 | 11 |
| FY2024 | 0 | 37 | 48 | 42 |
| FY2023 | 0 | 94 | 83 | 0 |
Source: Moderna FY2025 Form 10-K other-revenue note (https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/R24.htm). FY2023: grant $94 million, collaboration $83 million, licensing and royalty $0, stand-ready $0 (total $177 million). FY2024: grant $37 million, collaboration $48 million, licensing and royalty $42 million, stand-ready $0 (total $127 million). FY2025: grant $22 million, collaboration $13 million, licensing and royalty $11 million, stand-ready $80 million (total $126 million). Stand-ready is amounts recognized under long-term strategic agreements with government entities for maintaining mRNA manufacturing capacity and pandemic readiness.